| P50 | author | Xiulong Shen | Q96067887 |
| P2093 | author name string | David R Corey | |
| | Thazha P Prakash | |
| | Jonathan K Watts | |
| | Frank Rigo | |
| | Liande Li | |
| | Masad J Damha | |
| | Vivek K Sharma | |
| | Daniel O'Reilly | |
| | Michaela Norrbom | |
| | Zhongtian Liu | |
| P2860 | cites work | 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (2'F-ANA) modified oligonucleotides (ON) effect highly efficient, and persistent, gene silencing | Q25255757 |
| | Improvements in siRNA properties mediated by 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (FANA) | Q25257267 |
| | Activating frataxin expression by repeat-targeted nucleic acids | Q28272901 |
| | Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model | Q28743986 |
| | Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich's ataxia | Q30602174 |
| | Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. | Q31967436 |
| | Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing | Q34020246 |
| | Effect of chemical modifications on modulation of gene expression by duplex antigene RNAs that are complementary to non-coding transcripts at gene promoters | Q34080079 |
| | Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study. | Q34418695 |
| | R-loops associated with triplet repeat expansions promote gene silencing in Friedreich ataxia and fragile X syndrome. | Q35160930 |
| | Epigenetic therapy for Friedreich ataxia | Q35180607 |
| | Docosahexaenoic Acid Conjugation Enhances Distribution and Safety of siRNA upon Local Administration in Mouse Brain | Q37256184 |
| | The Hill equation: a review of its capabilities in pharmacological modelling | Q37339368 |
| | Friedreich ataxia: the clinical picture | Q37414025 |
| | Designing chemically modified oligonucleotides for targeted gene silencing | Q38037797 |
| | Mechanisms of transcriptional dysregulation in repeat expansion disorders | Q38238667 |
| | Synthesis and biological properties of triazole-linked locked nucleic acid | Q38287693 |
| | Friedreich Ataxia: current status and future prospects | Q38730963 |
| | Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich's ataxia can be reduced upon HDAC inhibition by vitamin B3. | Q39183027 |
| | Translating HDAC inhibitors in Friedreich's ataxia. | Q39230731 |
| | Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. | Q40241487 |
| | Antisense 2'-Deoxy, 2'-Fluroarabino Nucleic Acids (2'F-ANAs) Oligonucleotides: In Vitro Gymnotic Silencers of Gene Expression Whose Potency Is Enhanced by Fatty Acids | Q41111748 |
| | Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia | Q42226636 |
| | Efficient RNase H-directed cleavage of RNA promoted by antisense DNA or 2'F-ANA constructs containing acyclic nucleotide inserts. | Q44277171 |
| | Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs | Q48569299 |
| | Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy | Q89262117 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 1 | |
| P304 | page(s) | 23-33 | |
| P577 | publication date | 2018-01-17 | |
| P1433 | published in | Nucleic Acid Therapeutics | Q19297428 |
| P1476 | title | Activation of Frataxin Protein Expression by Antisense Oligonucleotides Targeting the Mutant Expanded Repeat | |
| P478 | volume | 28 | |